Literature DB >> 25762007

[Diabetic nephropathy: current diagnostics and treatment].

S Werth1, H Lehnert, J Steinhoff.   

Abstract

Diabetic kidney disease is a leading cause of renal failure in Germany. Albuminuria is an early diagnostic indicator of renal damage in diabetes and, aside from renal failure, a major risk factor of cardiovascular disease. An early diagnosis of diabetic kidney disease is of great importance to reduce associated cardiovascular mortality; glycemic control should aim for HbA1c levels of < 7 %. Guidelines on blood pressure differ, but it should generally be reduced to < 140/90 mmHg; stricter limits should be applied if albuminuria is present. ACE inhibitors (ACE-I) or angiotensin receptor blockers (ARB) should be preferred for blood pressure control. A combination of ACE-Is and ARBs or a renin-inhibitor therapy does not improve cardiovascular outcome, instead it increases the rate of adverse events, e.g., hyperkalemia or renal failure. Lipid control, usually with statins, should be started at an early phase of renal failure. Vitamin D receptor activation and uric acid reduction might play a future role in the treatment of diabetic kidney disease. Pharmacological modification of inflammatory signaling appears to be promising but is not yet of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25762007     DOI: 10.1007/s00108-014-3629-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Authors:  Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 10.121

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

Review 4.  Obesity, metabolic syndrome and diabetic nephropathy.

Authors:  Christine Maric; John E Hall
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

5.  Risk for ESRD in type 1 diabetes remains high despite renoprotection.

Authors:  Elizabeth T Rosolowsky; Jan Skupien; Adam M Smiles; Monika Niewczas; Bijan Roshan; Robert Stanton; John H Eckfeldt; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2011-02-25       Impact factor: 10.121

6.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

Review 7.  Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Authors:  Steven G Coca; Faramarz Ismail-Beigi; Nowreen Haq; Harlan M Krumholz; Chirag R Parikh
Journal:  Arch Intern Med       Date:  2012-05-28

8.  Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.

Authors:  Shin-ichi Araki; Masakazu Haneda; Daisuke Koya; Hideki Hidaka; Toshiro Sugimoto; Motohide Isono; Keiji Isshiki; Masami Chin-Kanasaki; Takashi Uzu; Atsunori Kashiwagi
Journal:  Diabetes       Date:  2007-03-14       Impact factor: 9.461

Review 9.  Diabetic nephropathy - complications and treatment.

Authors:  Andy Kh Lim
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-15

10.  Mortality rates in trials of subjects with type 2 diabetes.

Authors:  Ebrahim Barkoudah; Hicham Skali; Hajime Uno; Scott D Solomon; Marc A Pfeffer
Journal:  J Am Heart Assoc       Date:  2012-02-20       Impact factor: 5.501

View more
  2 in total

1.  PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.

Authors:  Esraa M Zakaria; Nabila N El-Maraghy; Ahmed F Ahmed; Abdelmonim A Ali; Hany M El-Bassossy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-21       Impact factor: 3.000

2.  The anti-inflammatory and antifibrotic effects of Coreopsis tinctoria Nutt on high-glucose-fat diet and streptozotocin-induced diabetic renal damage in rats.

Authors:  Lan Yao; Linlin Li; Xinxia Li; Hui Li; Yujie Zhang; Rui Zhang; Jian Wang; Xinmin Mao
Journal:  BMC Complement Altern Med       Date:  2015-09-07       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.